VINCENTTAMVINCENT H. TAM29.70508570000000-95.401808700000004595TAM, VINCENTH.Professorprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provinceAgreementvivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofRolevivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 156625425263332Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KWPediatric blood & cancerAgreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4.Pediatr Blood Cancer2014-09-27T00:00:002014Agreement among measurements and estimations of glomerular filtration in children with cancer.Authorship 79776Authorship 81885Authorship 84673Authorship 853655Authorship 891461Authorship 927821Authorship 961146Authorship 957595Authorship 1004536Authorship 1033746Authorship 1037443Authorship 1052457AMELIASOFJANAMELIA K. SOFJAN8284SOFJAN, AMELIAClinical Assistant ProfessorAuthorship 108582Authorship 154791Authorship 167895Authorship 192021Authorship 219116Authorship 226515Authorship 1601333Authorship 1602268Authorship 1613477Authorship 1615784Authorship 1617627Authorship 1618041Authorship 162743324377345Ou LC, Faulkner C, Tam V, Leiter JCHigh altitude medicine & biologyLiver function in rats acclimatized to a simulated altitude of 5500 m. High Alt Med Biol. 2013 Dec; 14(4):375-82.High Alt Med Biol2013-12-01T00:00:002013Liver function in rats acclimatized to a simulated altitude of 5500 m.25381169Zasowski E, Bland CM, Tam VH, Lodise TPThe Journal of antimicrobial chemotherapyIdentification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81.J Antimicrob Chemother2014-11-06T00:00:002014Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.25403674Phe K, Dao D, Palmer HR, Tam VHAntimicrobial agents and chemotherapyIn vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370.Antimicrob Agents Chemother2014-11-17T00:00:002014In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus.25459221Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JDThe Lancet. Infectious diseasesFramework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.Lancet Infect Dis2014-10-21T00:00:002014Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.25665726Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VHInternational journal of antimicrobial agentsCefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.Int J Antimicrob Agents2015-01-19T00:00:002015Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.25712358Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LDAntimicrobial agents and chemotherapyKidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May; 59(5):2930-3.Antimicrob Agents Chemother2015-02-23T00:00:002015Kidney injury associated with telavancin dosing regimen in an animal model.25712362Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VHAntimicrobial agents and chemotherapyAssessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.Antimicrob Agents Chemother2015-02-23T00:00:002015Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.Authorship 307911Authorship 382204Infectious Diseases, Infection Control, and Employee HealthMD AndersonISSAM IRAADISSAM I RAAD8617RAAD, ISSAM IProfessorAuthorship 424887Authorship 461441Authorship 494261Authorship 495804Authorship 522841Authorship 272108625652747Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VHThe Journal of antimicrobial chemotherapyRisk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.J Antimicrob Chemother2015-02-03T00:00:002015Risk factors for nephrotoxicity onset associated with polymyxin B therapy.Authorship 675596Authorship 706506Authorship 772411Authorship 821292Authorship 831933Authorship 868136Authorship 884866Authorship 904935Authorship 90665226643340Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VHAntimicrobial agents and chemotherapyCharacterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016 Feb; 60(2):1029-34.Antimicrob Agents Chemother2015-12-07T00:00:002015Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.Authorship 2977275Authorship 3000064Authorship 302330410865602Tam VH, Moore GE, Triller DM, Briceland LLJournal of intravenous nursing : the official publication of the Intravenous Nurses SocietyVancomycin peak serum concentration monitoring. J Intraven Nurs. 1999 Nov-Dec; 22(6):336-42.J Intraven Nurs1999-11-01T00:00:001999Vancomycin peak serum concentration monitoring.26324262Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VHAntimicrobial agents and chemotherapyAnalytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother. 2015 Nov; 59(11):7121-3.Antimicrob Agents Chemother2015-08-31T00:00:002015Analytical and functional determination of polymyxin B protein binding in serum.26372947Zhang D, Wu L, Chow DS, Tam VH, Rios DRJournal of pharmaceutical and biomedical analysisQuantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates. J Pharm Biomed Anal. 2016 Jan 05; 117:227-31.J Pharm Biomed Anal2015-09-05T00:00:002015Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates.26639227Patel TS, Cottreau JM, Hirsch EB, Tam VHDiagnostic microbiology and infectious diseaseImpact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8.Diagn Microbiol Infect Dis2015-10-28T00:00:002015Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia.10999505Tam VH, Mckinnon PS, Levine DP, Brandel SM, Rybak MJPharmacotherapyOnce-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy. 2000 Sep; 20(9):1116-9.Pharmacotherapy2000-09-01T00:00:002000Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review.11880957Lodise TP, McKinnon PS, Tam VH, Rybak MJClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaClinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002 Apr 01; 34(7):922-9.Clin Infect Dis2002-03-04T00:00:002002Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center.10369625Tam VH, Preston SL, Briceland LLThe Annals of pharmacotherapyOnce-daily aminoglycosides in the treatment of gram-positive endocarditis. Ann Pharmacother. 1999 May; 33(5):600-6.Ann Pharmacother1999-05-01T00:00:001999Once-daily aminoglycosides in the treatment of gram-positive endocarditis.15378439Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis REThe Journal of infectious diseasesPharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004 Oct 15; 190(8):1464-71.J Infect Dis2004-09-10T00:00:002004Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.74Professor10Assistant Professor27Clinical Assistant Professor29Clinical Associate Professor21Chair14Associate Professor6Adjunct Professor11147147McKinnon PS, Tam VHSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerNew antibiotics for infections caused by resistant organisms. Support Care Cancer. 2001 Jan; 9(1):8-10.Support Care Cancer2001-01-01T00:00:002001New antibiotics for infections caused by resistant organisms.12627928Rhoney DH, Tam VH, Parker D, McKinnon PS, Coplin WMPharmacotherapyDisposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4.Pharmacotherapy2003-03-01T00:00:002003Disposition of cefepime in the central nervous system of patients with external ventricular drains.16125032Walker P, Neuhauser MN, Tam VH, Willey JS, Palmer JL, Bruera E, Prince RAJournal of pain and symptom managementSubcutaneous administration of cefepime. J Pain Symptom Manage. 2005 Aug; 30(2):170-4.J Pain Symptom Manage2005-08-01T00:00:002005Subcutaneous administration of cefepime.12760858Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJAntimicrobial agents and chemotherapyPharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61.Antimicrob Agents Chemother2003-06-01T00:00:002003Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.16172104Tam VH, Nikolaou MThe Journal of antimicrobial chemotherapyMathematical modelling of resistance emergence. J Antimicrob Chemother. 2005 Nov; 56(5):983; author reply 983-4.J Antimicrob Chemother2005-09-19T00:00:002005Mathematical modelling of resistance emergence.12936990Tam VH, Preston SL, Drusano GLAntimicrobial agents and chemotherapyOptimal sampling schedule design for populations of patients. Antimicrob Agents Chemother. 2003 Sep; 47(9):2888-91.Antimicrob Agents Chemother2003-09-01T00:00:002003Optimal sampling schedule design for populations of patients.Authorship 3201836Authorship 320234726612873Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RFThe Journal of antimicrobial chemotherapyPharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30.J Antimicrob Chemother2015-11-26T00:00:002015Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients.16595813Tam VH, Adams S, LaRocco MT, Gerard LN, Gentry LO, Garey KWAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsAn integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm. 2006 Apr 15; 63(8):735-9.Am J Health Syst Pharm2006-04-15T00:00:002006An integrated pharmacoeconomic approach to antimicrobial formulary decision-making.16930922Tam VH, Kabbara SDiagnostic microbiology and infectious diseaseComparative performance of different stochastic methods to simulate drug exposure and variability in a population. Diagn Microbiol Infect Dis. 2006 Oct; 56(2):185-8.Diagn Microbiol Infect Dis2006-08-23T00:00:002006Comparative performance of different stochastic methods to simulate drug exposure and variability in a population.Authorship 325765627530844Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VHJournal of global antimicrobial resistanceAn institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 09; 6:75-77.J Glob Antimicrob Resist2016-05-04T00:00:002016An institutional review of antimicrobial stewardship interventions.17126534Falagas ME, Bliziotis IA, Tam VHInternational journal of antimicrobial agentsIntraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007 Jan; 29(1):9-25.Int J Antimicrob Agents2006-11-28T00:00:002006Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence.17431788Nikolaou M, Schilling AN, Vo G, Chang KT, Tam VHAnnals of biomedical engineeringModeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann Biomed Eng. 2007 Aug; 35(8):1458-70.Ann Biomed Eng2007-04-13T00:00:002007Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents.17617302Tam VH, Chang KT, LaRocco MT, Schilling AN, McCauley SK, Poole K, Garey KWDiagnostic microbiology and infectious diseasePrevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.Diagn Microbiol Infect Dis2007-07-01T00:00:002007Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.18279040Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KWClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaOutcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.Clin Infect Dis2008-03-15T00:00:002008Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.18505848Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, Nikolaou M, Quinn JP, Prince RA, Tam VHAntimicrobial agents and chemotherapyQuantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008 Aug; 52(8):2898-904.Antimicrob Agents Chemother2008-05-27T00:00:002008Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.18997127Yeh RF, Kuper KM, Coyle EA, Garey KW, Ikwuagwu JO, Maclayton DO, Mohr JF, Musick WL, Pass SE, Rios E, Tam VH, Houston Infectious Disease NetworkAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsSignificant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15; 65(22):e72-9.Am J Health Syst Pharm2008-11-15T00:00:002008Significant publications on infectious diseases pharmacotherapy in 2007.19037522Kwa AL, Tam VH, Falagas MEAnnals of the Academy of Medicine, SingaporePolymyxins: a review of the current status including recent developments. Ann Acad Med Singap. 2008 Oct; 37(10):870-83.Ann Acad Med Singap2008-10-01T00:00:002008Polymyxins: a review of the current status including recent developments.19129069Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VHJournal of chemotherapy (Florence, Italy)Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.J Chemother2008-12-01T00:00:002008Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia.15772138Tam VH, Schilling AN, Nikolaou MThe Journal of antimicrobial chemotherapyModelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother. 2005 May; 55(5):699-706.J Antimicrob Chemother2005-03-16T00:00:002005Modelling time-kill studies to discern the pharmacodynamics of meropenem.19736994Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, Hu MMolecular pharmaceuticsDisposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009 Nov-Dec; 6(6):1703-15.Mol Pharm2009-11-01T00:00:002009Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides.19744837Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VHInternational journal of antimicrobial agentsNephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4.Int J Antimicrob Agents2009-09-09T00:00:002009Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.19767379Kuper KM, Hirsch EB, Tam VH, Houston Infectious Diseases NetworkAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsSignificant publications on infectious diseases pharmacotherapy in 2008. Am J Health Syst Pharm. 2009 Oct 01; 66(19):1726-34.Am J Health Syst Pharm2009-10-01T00:00:002009Significant publications on infectious diseases pharmacotherapy in 2008.20045285He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VHInternational journal of antimicrobial agentsVariability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents. 2010 Mar; 35(3):308-10.Int J Antimicrob Agents2009-12-31T00:00:002009Variability of polymyxin B major components in commercial formulations.20065055Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH, Network for Antimicrobial Resistance Surveillance (Singapore)Antimicrobial agents and chemotherapySurveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8.Antimicrob Agents Chemother2010-01-11T00:00:002010Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.15964503Tam VH, Schilling AN, Melnick DA, Coyle EADiagnostic microbiology and infectious diseaseComparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005 Jun; 52(2):145-51.Diagn Microbiol Infect Dis2005-06-01T00:00:002005Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa.16120792Chen J, Wang S, Jia X, Bajimaya S, Lin H, Tam VH, Hu MDrug metabolism and disposition: the biological fate of chemicalsDisposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos. 2005 Dec; 33(12):1777-84.Drug Metab Dispos2005-08-24T00:00:002005Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition.20592326He J, Figueroa DA, Lim TP, Chow DS, Tam VHAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsStability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15; 67(14):1191-4.Am J Health Syst Pharm2010-07-15T00:00:002010Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C.16195922Nikolaou M, Tam VHJournal of mathematical biologyA new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. J Math Biol. 2006 Feb; 52(2):154-82.J Math Biol2005-09-29T00:00:002005A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations.16304153Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EAAntimicrobial agents and chemotherapyOptimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Dec; 49(12):4920-7.Antimicrob Agents Chemother2005-12-01T00:00:002005Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.15504858Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher ANAntimicrobial agents and chemotherapyNovel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother. 2004 Nov; 48(11):4315-21.Antimicrob Agents Chemother2004-11-01T00:00:002004Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.Health 2 4849 Calhoun Road, Room 4041Houston, TX 77204-5039Houston77204-5039TX16423490Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GLDiagnostic microbiology and infectious diseasePharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30.Diagn Microbiol Infect Dis2006-01-19T00:00:002006Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies.Authorship 328396427697755Manchandani P, Dubrovskaya Y, Gao S, Tam VHAntimicrobial agents and chemotherapyComparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.Antimicrob Agents Chemother2016-10-21T00:00:002016Comparative Pharmacokinetic Profiling of Different Polymyxin B Components.21709096Tam VH, Cao H, Ledesma KR, Hu MAntimicrobial agents and chemotherapyIn vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1.Antimicrob Agents Chemother2011-06-27T00:00:002011In vitro potency of various polymyxin B components.21807974Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VHAntimicrobial agents and chemotherapyQuantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5.Antimicrob Agents Chemother2011-08-01T00:00:002011Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model.21868287Singh R, Tam VHCurrent opinion in pharmacologyOptimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct; 11(5):453-6.Curr Opin Pharmacol2011-08-23T00:00:002011Optimizing dosage to prevent emergence of resistance - lessons from in vitro models.22232512Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VHThe Journal of antimicrobial chemotherapyPredicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother. 2012 Apr; 67(4):928-32.J Antimicrob Chemother2012-01-09T00:00:002012Predicting bacterial fitness cost associated with drug resistance.15995955Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GLThe Journal of infectious diseasesBacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis. 2005 Aug 01; 192(3):420-8.J Infect Dis2005-07-05T00:00:002005Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.16080101Kwa AL, Loh C, Low JG, Kurup A, Tam VHClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaNebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.Clin Infect Dis2005-07-20T00:00:002005Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.22526311Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VHAntimicrobial agents and chemotherapyIn vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.Antimicrob Agents Chemother2012-04-23T00:00:002012In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.17024796Garey KW, Kumar N, Dao T, Tam VH, Gentry LOJournal of chemotherapy (Florence, Italy)Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.J Chemother2006-08-01T00:00:002006Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients.17300905Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VHDiagnostic microbiology and infectious diseaseThe impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104.Diagn Microbiol Infect Dis2007-02-14T00:00:002007The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia.17492598Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GLThe Journal of infectious diseasesImpact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27.J Infect Dis2007-05-02T00:00:002007Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.16870751Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EAAntimicrobial agents and chemotherapyComparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Aug; 50(8):2626-31.Antimicrob Agents Chemother2006-08-01T00:00:002006Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.16882763Wang SW, Chen J, Jia X, Tam VH, Hu MDrug metabolism and disposition: the biological fate of chemicalsDisposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos. 2006 Nov; 34(11):1837-48.Drug Metab Dispos2006-08-01T00:00:002006Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties.17916420Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VHDiagnostic microbiology and infectious diseasePharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7.Diagn Microbiol Infect Dis2007-10-04T00:00:002007Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.17913722Tam VH, Schilling AN, Poole K, Nikolaou MThe Journal of antimicrobial chemotherapyMathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007 Dec; 60(6):1302-9.J Antimicrob Chemother2007-10-03T00:00:002007Mathematical modelling response of Pseudomonas aeruginosa to meropenem.17927138Liu X, Tam VH, Hu MMolecular pharmaceuticsDisposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm. 2007 Nov-Dec; 4(6):873-82.Mol Pharm2007-10-10T00:00:002007Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA.18447592Yuan Z, Tam VHExpert opinion on investigational drugsPolymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May; 17(5):661-8.Expert Opin Investig Drugs2008-05-01T00:00:002008Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.18377809Lim TP, Garey KW, Tam VHCurrent infectious disease reportsPharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. Curr Infect Dis Rep. 2008 Mar; 10(1):9-13.Curr Infect Dis Rep2008-03-01T00:00:002008Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies.19028631Garey KW, Martorell MV, Vo QP, Tam VHJournal of chemotherapy (Florence, Italy)Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4.J Chemother2008-10-01T00:00:002008Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa.19037515Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VHAnnals of the Academy of Medicine, SingaporeIndependent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008 Oct; 37(10):826-30.Ann Acad Med Singap2008-10-01T00:00:002008Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures.19589810Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VHThe Journal of antimicrobial chemotherapyPharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother. 2009 Sep; 64(3):556-62.J Antimicrob Chemother2009-07-09T00:00:002009Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.19631096Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis REDiagnostic microbiology and infectious diseaseIn vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009 Aug; 64(4):427-33.Diagn Microbiol Infect Dis2009-08-01T00:00:002009In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.Authorship 6527267Authorship 6531889Authorship 653686627543655Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VHThe Journal of antimicrobial chemotherapyPredicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.J Antimicrob Chemother2016-08-19T00:00:002016Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.27799209Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VHAntimicrobial agents and chemotherapyDosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).Antimicrob Agents Chemother2016-12-27T00:00:002016Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.28096166Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VHAntimicrobial agents and chemotherapyRole of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 04; 61(4).Antimicrob Agents Chemother2017-03-24T00:00:002017Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity.20086165Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KWAntimicrobial agents and chemotherapyPrevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4.Antimicrob Agents Chemother2010-01-19T00:00:002010Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.20378670Hirsch EB, Tam VHThe Journal of antimicrobial chemotherapyDetection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun; 65(6):1119-25.J Antimicrob Chemother2010-04-08T00:00:002010Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.Authorship 678084120156065Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VHThe Journal of infectious diseasesQuantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis. 2010 Mar 15; 201(6):889-97.J Infect Dis2010-03-15T00:00:002010Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model.28158470Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, S?nchez-D?az AM, Zamorano L, Oliver A, Cant?n RThe Journal of antimicrobial chemotherapyDetermining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428.J Antimicrob Chemother2017-05-01T00:00:002017Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.20805390Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VHAntimicrobial agents and chemotherapyMathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov; 54(11):4739-43.Antimicrob Agents Chemother2010-08-30T00:00:002010Mathematical modeling to characterize the inoculum effect.21058913Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, Dupont HLClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaA common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.Clin Infect Dis2010-11-08T00:00:002010A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection.21164382Salvatore CM, Abdelraouf K, Hsing DD, Tam VHThe Pediatric infectious disease journalPharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J. 2011 Jun; 30(6):537-9.Pediatr Infect Dis J2011-06-01T00:00:002011Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia.21253559Tam VH, Nikolaou MPLoS computational biologyA novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol. 2011 Jan 06; 7(1):e1001043.PLoS Comput Biol2011-01-06T00:00:002011A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design.20651305Palmer HR, Cottreau JM, Garey KW, Hirsch EB, Musick WL, Tam VH, Yeh RF, Houston Infectious Diseases NetworkAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsSignificant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug; 67(15):e34-42.Am J Health Syst Pharm2010-08-01T00:00:002010Significant publications on infectious diseases pharmacotherapy in 2009.20660686Singh R, Ledesma KR, Chang KT, Tam VHAntimicrobial agents and chemotherapyImpact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother. 2010 Oct; 54(10):4262-8.Antimicrob Agents Chemother2010-07-26T00:00:002010Impact of recA on levofloxacin exposure-related resistance development.21507926Kwa AL, Falagas ME, Michalopoulos A, Tam VHClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaBenefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis. 2011 May; 52(10):1278-9; author reply 1279-80.Clin Infect Dis2011-05-01T00:00:002011Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence?20715920Hirsch EB, Tam VHExpert review of pharmacoeconomics & outcomes researchImpact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug; 10(4):441-51.Expert Rev Pharmacoecon Outcomes Res2010-08-01T00:00:002010Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.Authorship 101165422058103Palmer HR, Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KWAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsImproving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15; 68(22):2170-4.Am J Health Syst Pharm2011-11-15T00:00:002011Improving patient care through implementation of an antimicrobial stewardship program.22232279Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, Tam VHAntimicrobial agents and chemotherapyTemporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5.Antimicrob Agents Chemother2012-01-09T00:00:002012Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.21415038Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VHThe Journal of antimicrobial chemotherapyEffect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother. 2011 Jun; 66(6):1311-7.J Antimicrob Chemother2011-03-17T00:00:002011Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa.Authorship 784853822764323Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HRThe Annals of pharmacotherapyCorrelation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1120-2.Ann Pharmacother2012-07-03T00:00:002012Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria.21507928Kwa AL, Abdelraouf K, Low JG, Tam VHClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1.Clin Infect Dis2011-05-01T00:00:002011Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report.27239695Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, Sulaiman Z, Tam VH, Lye DC, Fisher DAJournal of chemotherapy (Florence, Italy)Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29.J Chemother2016-05-30T00:00:002016Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections.22056006Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VHDiagnostic microbiology and infectious diseaseA model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102.Diagn Microbiol Infect Dis2011-11-03T00:00:002011A model to predict mortality following Pseudomonas aeruginosa bacteremia.Authorship 840355628264853Zhou J, Ledesma KR, Chang KT, Abodakpi H, Gao S, Tam VHAntimicrobial agents and chemotherapyPharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).Antimicrob Agents Chemother2017-04-24T00:00:002017Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.Authorship 8682822Authorship 868461328320712Tran TT, Tam VH, Murray BE, Arias CA, Singh KVAntimicrobial agents and chemotherapyEfficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).Antimicrob Agents Chemother2017-05-24T00:00:002017Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.28333250Zhou J, Tran BT, Tam VHThe Journal of antimicrobial chemotherapyThe complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634.J Antimicrob Chemother2017-06-01T00:00:002017The complexity of minocycline serum protein binding.Authorship 8690591028409203T?ngd?n T, Ramos Mart?n V, Felton TW, Nielsen EI, Marchand S, Br?ggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA, Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and PharIntensive care medicineThe role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017 Jul; 43(7):1021-1032.Intensive Care Med2017-04-13T00:00:002017The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Authorship 869742328483961Singh KV, Tran TT, Nannini EC, Tam VH, Arias CA, Murray BEAntimicrobial agents and chemotherapyEfficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7).Antimicrob Agents Chemother2017-06-27T00:00:002017Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.Authorship 8702771128559261Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JAAntimicrobial agents and chemotherapyThe Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).Antimicrob Agents Chemother2017-07-25T00:00:002017The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques.11718503Kwa AL, Tam VH, Rybak MJPharmacotherapyRhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002.Pharmacotherapy2001-08-01T00:00:002001Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review.12627925Tam VH, Louie A, Lomaestro BM, Drusano GLPharmacotherapyIntegration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003 Mar; 23(3):291-5.Pharmacotherapy2003-03-01T00:00:002003Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.12865415Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GLThe Journal of clinical investigationApplication of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul; 112(2):275-85.J Clin Invest2003-07-01T00:00:002003Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.14695034Tam VH, Preston SL, Drusano GLPharmacotherapyComparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Pharmacotherapy. 2003 Dec; 23(12):1545-9.Pharmacotherapy2003-12-01T00:00:002003Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.16127031Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis REAntimicrobial agents and chemotherapyPharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30.Antimicrob Agents Chemother2005-09-01T00:00:002005Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.16377702Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GLAntimicrobial agents and chemotherapyQuinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Jan; 50(1):310-7.Antimicrob Agents Chemother2006-01-01T00:00:002006Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.16436698Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis REAntimicrobial agents and chemotherapyPharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Feb; 50(2):469-73.Antimicrob Agents Chemother2006-02-01T00:00:002006Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.16626903Boucher AN, Tam VHDiagnostic microbiology and infectious diseaseMathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis. 2006 Aug; 55(4):319-25.Diagn Microbiol Infect Dis2006-04-19T00:00:002006Mathematical formulation of additivity for antimicrobial agents.16954312Tam VH, Kabbara S, Yeh RF, Leary RHAntimicrobial agents and chemotherapyImpact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother. 2006 Nov; 50(11):3950-2.Antimicrob Agents Chemother2006-09-05T00:00:002006Impact of sample size on the performance of multiple-model pharmacokinetic simulations.17116679Tam VH, Louie A, Deziel MR, Liu W, Drusano GLAntimicrobial agents and chemotherapyThe relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7.Antimicrob Agents Chemother2006-11-20T00:00:002006The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.17359326Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolans K, Quinn JP, Garey KWClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious DiseasesPrevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2007 Apr; 13(4):413-8.Clin Microbiol Infect2007-04-01T00:00:002007Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa.17914915Kwa A, Kasiakou SK, Tam VH, Falagas MEExpert review of anti-infective therapyPolymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21.Expert Rev Anti Infect Ther2007-10-01T00:00:002007Polymyxin B: similarities to and differences from colistin (polymyxin E).18334494Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DAThe Journal of antimicrobial chemotherapyRisk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008 Jul; 62(1):168-71.J Antimicrob Chemother2008-03-10T00:00:002008Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.18725438Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou MAntimicrobial agents and chemotherapyPharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93.Antimicrob Agents Chemother2008-08-25T00:00:002008Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.18990530Garey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VHDiagnostic microbiology and infectious diseaseIncreased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn Microbiol Infect Dis. 2009 Jan; 63(1):81-6.Diagn Microbiol Infect Dis2008-11-06T00:00:002008Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin.19022780Tam VH, Hou J, Kwa AL, Prince RAThe Journal of antimicrobial chemotherapyComment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother. 2009 Mar; 63(3):627-8; author reply 628-9.J Antimicrob Chemother2008-11-19T00:00:002008Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma.19304437Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JPDiagnostic microbiology and infectious diseaseKilling of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009 Jun; 64(2):166-71.Diagn Microbiol Infect Dis2009-03-21T00:00:002009Killing of Escherichia coli by beta-lactams at different inocula.21251574Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VHDiagnostic microbiology and infectious diseaseEmergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis. 2011 Feb; 69(2):234-5.Diagn Microbiol Infect Dis2011-02-01T00:00:002011Emergence of KPC-producing Klebsiella pneumoniae in Texas.21393141Bhagunde P, Singh R, Ledesma KR, Chang KT, Nikolaou M, Tam VHThe Journal of antimicrobial chemotherapyModelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86.J Antimicrob Chemother2011-03-03T00:00:002011Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.22330927Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VHAntimicrobial agents and chemotherapyNovel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.Antimicrob Agents Chemother2012-02-13T00:00:002012Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors.22345291Tiong CT, Chen C, Zhang SJ, Li J, Soshilov A, Denison MS, Lee LS, Tam VH, Wong SP, Xu HE, Yong ELCarcinogenesisA novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERa protein. Carcinogenesis. 2012 May; 33(5):1089-97.Carcinogenesis2012-02-16T00:00:002012A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERa protein.22610031Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KWAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsEvaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.Am J Health Syst Pharm2012-06-01T00:00:002012Evaluation of a daptomycin dose-optimization protocol.22687519Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VHAntimicrobial agents and chemotherapyCharacterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.Antimicrob Agents Chemother2012-06-11T00:00:002012Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.Authorship 87858716Authorship 8815777Authorship 8830721Authorship 8832126Authorship 883913426599303Cheung CL, Sing CW, Tang CS, Cheng VK, Pirmohamed M, Choi CH, Hung CS, Lau EY, Lee KF, Mak MW, Leung JY, Wong TW, Ho AY, Chan KW, Hung V, Tam V, Siu SC, Pang HK, Wat WZ, Lee HH, Chung CT, Hue RS, Sham PC, Cheung BM, Wong IC, Tan KC, Kung AClinical pharmacology and therapeuticsHLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther. 2016 May; 99(5):555-61.Clin Pharmacol Ther2016-01-12T00:00:002016HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis.29418013Tam VH, P?rez C, Ledesma KR, Lewis REMicrobiology and immunologyTranscriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294.Microbiol Immunol2018-03-26T00:00:002018Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa.29125052Abodakpi H, Chang KT, S?nchez D?az AM, Cant?n R, Lasco TM, Chan K, Sofjan AK, Tam VHJournal of chemotherapy (Florence, Italy)Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119.J Chemother2017-11-10T00:00:002017Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital.29238962Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VHClinical pharmacology and therapeuticsPopulation Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.Clin Pharmacol Ther2018-01-08T00:00:002018Population Pharmacokinetics of Polymyxin B.28848003Babic JT, Manchandani P, Ledesma KR, Tam VHAntimicrobial agents and chemotherapyEvaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 11; 61(11).Antimicrob Agents Chemother2017-10-24T00:00:002017Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity.23341128He J, Gao S, Hu M, Chow DS, Tam VHThe Journal of antimicrobial chemotherapyA validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10.J Antimicrob Chemother2013-01-22T00:00:002013A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies.Authorship 106391TODDLASCOTODD LASCO13953LASCO, TODDAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessorD011112Chemicals & Drugs14530.936613Polymyxin BAuthorship 1074175Authorship 1074601D000900Chemicals & Drugs87929850.399068Anti-Bacterial AgentsAuthorship 1068859D011550Living Beings1022330.840938Pseudomonas aeruginosaAuthorship 1038734Authorship 1092233Authorship 9192524Authorship 9367374Authorship 9384976Authorship 9388401329101084Skoglund E, Ledesma KR, Lasco TM, Tam VHJournal of global antimicrobial resistanceCeftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155.J Glob Antimicrob Resist2017-10-31T00:00:002017Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.30710469Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KSPharmacotherapyInternational Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39.Pharmacotherapy2019-01-01T00:00:002019International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).30530606Abodakpi H, Chang KT, Gao S, S?nchez-D?az AM, Cant?n R, Tam VHAntimicrobial agents and chemotherapyOptimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).Antimicrob Agents Chemother2019-01-29T00:00:002019Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae.30675406Skoglund E, Abodakpi H, Rios R, Diaz L, De La Cadena E, Dinh AQ, Ardila J, Miller WR, Munita JM, Arias CA, Tam VH, Tran TTCase reports in infectious diseasesIn Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Rep Infect Dis. 2018; 2018:9095203.Case Rep Infect Dis2018-12-23T00:00:002018In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways.D040981Living Beings27520.940689Acinetobacter baumanniiD011552Disorders811560.87164Pseudomonas Infections2013-09-28NIHTAM, VINCENT H2010-03-29Clinical Pharmacology of Polymyxin BR15AI0896712024-07-31NIHTAM, VINCENT H2018-08-15Personalized Antimicrobial Combinations to Combat ResistanceR01AI1402872016-07-31NIHTAM, VINCENT H2014-08-01Optimized Antimicrobial Combinations to Suppress ResistanceR56AI111793Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPharmacological & Pharmaceutical SciencesDepartment of MedicineDepartment of Pathology & ImmunologyMedicine-Gastroenterology & HepatolPathologyBaylor College of MedicineUniversity of Houston College of PharmacyDAVIDGRAHAMDAVID GRAHAM29.70508570000000-95.401808700000002360GRAHAM, DAVIDProfessorJEFFREYSHERERJEFFREY T. SHERER29.70508570000000-95.401808700000004599SHERER, JEFFREYClinical Associate ProfessorDHARASURATIDHARA N. SURATI29.70508570000000-95.401808700000004611SURATI, DHARAClinical Assistant ProfessorAuthorship 1103908LUANTRUONGLUAN TRUONG29.70508570000000-95.401808700000002829TRUONG, LUANAdjunct ProfessorAuthorship 1091432YOSHIOYAMAOKAYOSHIO YAMAOKA0.000000000000000.000000000000003531YAMAOKA, YOSHIOProfessor14.26550.00461772487research areas4.062360.017157419coauthor of342.82624.649860similar to11189selected publicationsCATHERINEHATFIELDCATHERINE L. HATFIELD29.70508570000000-95.401808700000004623HATFIELD, CATHERINEClinical Associate ProfessorKEVINGAREYKEVIN W. GAREY29.70508570000000-95.401808700000004636GAREY, KEVINProfessor. Chair, Department of Pharmacy Practice and Translational Research.MINGHUMING HU29.70508570000000-95.401808700000004600HU, MINGProfessorNANCYORDONEZNANCY ORDONEZ29.70508570000000-95.401808700000004620ORDONEZ, NANCYClinical Assistant Professor. Assistant Dean of Experiential ProgramsAuthorship 9412004Authorship 9422305Authorship 942373430833428Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JLAntimicrobial agents and chemotherapyGenerating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 05; 63(5).Antimicrob Agents Chemother2019-04-25T00:00:002019Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.30522794Phe K, Bowers DR, Babic JT, Tam VHDiagnostic microbiology and infectious diseaseOutcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.Diagn Microbiol Infect Dis2018-11-09T00:00:002018Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia.30664934Abodakpi H, Chang KT, Zhou J, Byerly C, Tam VHClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious DiseasesA novel framework to compare the effectiveness of ?-lactamase inhibitors against extended-spectrum ?-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect. 2019 Sep; 25(9):1154.e9-1154.e14.Clin Microbiol Infect2019-01-18T00:00:002019A novel framework to compare the effectiveness of ?-lactamase inhibitors against extended-spectrum ?-lactamase-producing Enterobacteriaceae.TIMOTHYPALZKILLTIMOTHY PALZKILL0.000000000000000.000000000000003364PALZKILL, TIMOTHYChairMEGHANATRIVEDIMEGHANA V. TRIVEDI29.70508570000000-95.401808700000004591TRIVEDI, MEGHANAAssociate ProfessorAuthorship 127316223977938Bowers DR, Tam VHExpert review of anti-infective therapyPseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug; 11(8):831-7.Expert Rev Anti Infect Ther2013-08-01T00:00:002013Pseudomonas aeruginosa treatment and transmission reduction.Authorship 953019231364083Pogue JM, Tam VHAdvances in experimental medicine and biologyToxicity in Patients. Adv Exp Med Biol. 2019; 1145:289-304.Adv Exp Med Biol2019-01-01T00:00:002019Toxicity in Patients.Authorship 953303331383269Abodakpi H, Wanger A, Tam VHClinics in laboratory medicineWhat the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ?-Lactam/?-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 09; 39(3):473-485.Clin Lab Med2019-07-06T00:00:002019What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ?-Lactam/?-Lactamase Inhibitor Combinations.80Professor. Chair, Department of Pharmacy Practice and Translational Research.28Clinical Assistant Professor. Assistant Dean of Experiential ProgramsAuthorship 956518631565449Skoglund E, Abodakpi H, Rios R, Diaz L, De La Cadena E, Dinh AQ, Ardila J, Miller WR, Munita JM, Arias CA, Tam VH, Tran TTCase reports in infectious diseasesCorrigendum to "In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways". Case Rep Infect Dis. 2019; 2019:8314349.Case Rep Infect Dis2019-09-02T00:00:002019Corrigendum to "In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways".true1Clinical Assistant Professor. Assistant Dean of Experiential ProgramsClinical Assistant Professor. Assistant Dean of Experiential Programstrue1Clinical Associate ProfessorClinical Associate Professortrue1Professor. Chair, Department of Pharmacy Practice and Translational Research.Professor. Chair, Department of Pharmacy Practice and Translational Research.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Clinical Assistant ProfessorClinical Assistant Professortrue1Clinical Assistant ProfessorClinical Assistant ProfessorPharmacy Practice and Translational Researchtrue1Assistant ProfessorAssistant ProfessorAuthorship 961656531770603Xie LX, Zhou J, Ledesma KR, Merlau PR, Tam VHJournal of global antimicrobial resistanceThe impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.J Glob Antimicrob Resist2019-11-23T00:00:002019The impact of serum protein binding on bacterial killing of minocycline.true1Clinical Associate ProfessorClinical Associate ProfessorAuthorship 974614131871078Tam VH, Cohen DN, Ledesma KR, Guillory B, Chan K, Garey KWAntimicrobial agents and chemotherapyLocal Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3).Antimicrob Agents Chemother2020-02-21T00:00:002020Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model.Authorship 1138092true1ProfessorProfessorAuthorship 11120911Authorship 988255532343148Chan K, Wang W, Ledesma KR, Yin T, Tam VHBioanalysisA robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies. Bioanalysis. 2020 Apr; 12(7):445-454.Bioanalysis2020-04-28T00:00:002020A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies.Authorship 1160891Authorship 9924914Authorship 992808231256175Quoc Hoang TA, Tam V, Thang HVThe Medical journal of MalaysiaPlasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease. Med J Malaysia. 2019 06; 74(3):209-214.Med J Malaysia2019-06-01T00:00:002019Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease.32571819Chan K, Ledesma KR, Wang W, Tam VHAntimicrobial agents and chemotherapyCharacterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 08 20; 64(9).Antimicrob Agents Chemother2020-08-20T00:00:002020Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model.Authorship 9949613Authorship 995219632691832Phe K, Heil EL, Tam VHThe Journal of infectious diseasesOptimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review. J Infect Dis. 2020 07 21; 222(Suppl 2):S132-S141.J Infect Dis2020-07-21T00:00:002020Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.32710435Dhaese S, Heffernan A, Liu D, Abdul-Aziz MH, Stove V, Tam VH, Lipman J, Roberts JA, De Waele JJClinical pharmacokineticsProlonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250.Clin Pharmacokinet2020-10-01T00:00:002020Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.Authorship 1002348133035321Tam VH, Abodakpi H, Wang W, Ledesma KR, Merlau PR, Chan K, Altman R, Tran TT, Nikolaou M, Sofjan AKThe Journal of antimicrobial chemotherapyOptimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.J Antimicrob Chemother2021-01-01T00:00:002021Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria.Authorship 10047287Authorship 10048995Authorship 1005412133166758Zidaru A, Eales BM, Wang W, Merlau PR, Lasco TM, Sofjan AK, Tam VHJournal of global antimicrobial resistanceMIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387.J Glob Antimicrob Resist2020-11-06T00:00:002020MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates.33177185Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici LClinical microbiology reviewsNew ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).Clin Microbiol Rev2020-11-11T00:00:002020New ?-Lactam-?-Lactamase Inhibitor Combinations.33217914Tam VH, Lee LS, Ng TM, Lim TP, Cherng BPZ, Adewusi H, Hee KH, Ding Y, Chung SJ, Ling LM, Chlebicki P, Kwa ALH, Lye DCMicroorganismsPerformance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. Microorganisms. 2020 Nov 18; 8(11).Microorganisms2020-11-18T00:00:002020Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures.Authorship 1006166533258161Ng TM, Heng ST, Oon J, Chan M, Tam VHJournal of clinical pharmacologyValidation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809.J Clin Pharmacol2020-12-16T00:00:002020Validation of Vancomycin Dosing Guidance During Transition of Care.Authorship 1008667333425938Ferry T, Lodise TP, Gallagher JC, Forestier E, Goutelle S, Tam VH, Mohr JF, Roubaud-Baudron CFrontiers in medicineOutpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Front Med (Lausanne). 2020; 7:585658.Front Med (Lausanne)2020-12-23T00:00:002020Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections.Authorship 1010009533504504Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici LClinical microbiology reviewsErratum for Yahav et al., "New ?-Lactam-?-Lactamase Inhibitor Combinations". Clin Microbiol Rev. 2021 Mar 17; 34(2).Clin Microbiol Rev2021-01-27T00:00:002021Erratum for Yahav et al., "New ?-Lactam-?-Lactamase Inhibitor Combinations".Authorship 1203317Authorship 1012542333645440Khan S, Phe K, Tam VHJournal of chemotherapy (Florence, Italy)Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.J Chemother2021-03-01T00:00:002021Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia.Authorship 1164014Authorship 1146935Authorship 1212571Authorship 1214964Authorship 1024256434196607Tu Y, Wang L, Rong Y, Tam V, Yin T, Gao S, Singh R, Hu MeLifeHepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. Elife. 2021 07 01; 10.Elife2021-07-01T00:00:002021Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats.Authorship 127191Authorship 1031928634680836Eales BM, Hudson CS, Kesisoglou I, Wang W, Nikolaou M, Tam VHAntibiotics (Basel, Switzerland)Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model. Antibiotics (Basel). 2021 Oct 16; 10(10).Antibiotics (Basel)2021-10-16T00:00:002021Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model.Authorship 1032348234694874Eales BM, Tam VHAntimicrobial agents and chemotherapyCase Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0199621.Antimicrob Agents Chemother2021-10-25T00:00:002021Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection.Authorship 132161Authorship 1033179134806561Tam VH, Hudson CS, Merlau PR, Shields RKJournal of chemotherapy (Florence, Italy)Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346.J Chemother2021-11-22T00:00:002021Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates.Authorship 1181471Authorship 1034648434849535Zidaru A, Phe K, Lasco TM, Tam VHAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsAn integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471.Am J Health Syst Pharm2022-03-07T00:00:002022An integrated approach to evaluate different tetracycline derivatives for formulary decisions.Authorship 10357074Authorship 1035732534922054Zidaru A, Sofjan AK, Devarajan SR, Tam VHJournal of global antimicrobial resistanceClinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. J Glob Antimicrob Resist. 2022 06; 29:551-552.J Glob Antimicrob Resist2021-12-15T00:00:002021Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection.34924641Kesisoglou I, Eales BM, Ledesma KR, Merlau PR, Tam VH, Wang W, Nikolaou MComputers & chemical engineeringSIMULTANEOUS IN VITRO SIMULATION OF MULTIPLE ANTIMICROBIAL AGENTS WITH DIFFERENT ELIMINATION HALF-LIVES IN A PRE-CLINICAL INFECTION MODEL. Comput Chem Eng. 2021 Dec; 155.Comput Chem Eng2021-09-13T00:00:002021SIMULTANEOUS IN VITRO SIMULATION OF MULTIPLE ANTIMICROBIAL AGENTS WITH DIFFERENT ELIMINATION HALF-LIVES IN A PRE-CLINICAL INFECTION MODEL.Authorship 1036771434994371Garcia CR, Malik MH, Biswas S, Tam VH, Rumbaugh KP, Li W, Liu XBiomaterials scienceNanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils. Biomater Sci. 2022 Feb 01; 10(3):633-653.Biomater Sci2022-02-01T00:00:002022Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils.Authorship 1191461Authorship 1041516235250117Kesisoglou I, Tam VH, Tomaras AP, Nikolaou MComputers & chemical engineeringDiscerning in vitro pharmacodynamics from OD measurements: A model-based approach. Comput Chem Eng. 2022 Feb; 158.Comput Chem Eng2021-12-16T00:00:002021Discerning in vitro pharmacodynamics from OD measurements: A model-based approach.Authorship 149217Authorship 1366115Authorship 1370629Authorship 10450396Authorship 1045095635508286Bai B, Chen C, Zhao Y, Xu G, Yu Z, Tam VH, Wen ZJournal of global antimicrobial resistanceIn vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China. J Glob Antimicrob Resist. 2022 09; 30:66-74.J Glob Antimicrob Resist2022-05-01T00:00:002022In vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China.27028298Shariff M, Quik M, Holgate J, Morgan M, Patkar OL, Tam V, Belmer A, Bartlett SEPloS oneNeuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake. PLoS One. 2016; 11(3):e0150270.PLoS One2016-03-30T00:00:002016Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.24016799He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VHInternational journal of antimicrobial agentsPharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.Int J Antimicrob Agents2013-08-22T00:00:002013Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.24107410Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JDClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaConsistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan; 58(1):139-41.Clin Infect Dis2013-10-08T00:00:002013Consistent global approach on reporting of colistin doses to promote safe and effective use.Authorship 10552388Authorship 10627122Authorship 10604011Authorship 10612794Authorship 1058737436540388Chua HC, Tam VHOpen forum infectious diseasesOptimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools. Open Forum Infect Dis. 2022 Dec; 9(12):ofac626.Open Forum Infect Dis2022-12-16T00:00:002022Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools.36322455Tu Y, Wang L, Rong Y, Tam V, Yin T, Gao S, Singh R, Hu MeLifeCorrection: Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. Elife. 2022 Nov 02; 11.Elife2022-11-02T00:00:002022Correction: Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats.36335752Kesisoglou I, Eales BM, Merlau PR, Tam VH, Nikolaou MComputer methods and programs in biomedicineDeciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212.Comput Methods Programs Biomed2022-11-01T00:00:002022Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach.36308002Bai B, Eales BM, Huang W, Ledesma KR, Merlau PR, Li G, Yu Z, Tam VHVirulenceClinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.Virulence2022-12-01T00:00:002022Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii.36031868Tam VH, Merlau PR, Hudson CS, Kline EG, Eales BM, Smith J, Sofjan AK, Shields RKThe Journal of antimicrobial chemotherapyOptimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.J Antimicrob Chemother2022-10-28T00:00:002022Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.Authorship 1063328436731874Eales BM, Bai B, Merlau PR, Tam VHLetters in applied microbiologyGrowth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2).Lett Appl Microbiol2023-02-16T00:00:002023Growth of Acinetobacter baumannii impacted by iron chelation.Authorship 1064289236804371Gatti M, Tam VH, Gaibani P, Cojutti PG, Viale P, Pea FInternational journal of antimicrobial agentsA novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.Int J Antimicrob Agents2023-02-18T00:00:002023A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections.Authorship 1069465337206682Bhagunde PR, Nikolaou M, Tam VHAIChE journal. American Institute of Chemical EngineersModeling Heterogeneous Bacterial Populations Exposed to Antibiotics: The Logistic-Dynamics Case. AIChE J. 2015 Aug; 61(8):2385-2393.AIChE J2015-05-19T00:00:002015Modeling Heterogeneous Bacterial Populations Exposed to Antibiotics: The Logistic-Dynamics Case.Authorship 10723832Authorship 1072682537376120Nikolaou M, Tam VHPharmaceuticsRapid In Vitro Assessment of Antimicrobial Drug Effect Bridging Clinically Relevant Pharmacokinetics: A Comprehensive Methodology. Pharmaceutics. 2023 Jun 07; 15(6).Pharmaceutics2023-06-07T00:00:002023Rapid In Vitro Assessment of Antimicrobial Drug Effect Bridging Clinically Relevant Pharmacokinetics: A Comprehensive Methodology.37433386Hudson CS, Smith JE, Eales BM, Nikolaou M, Tam VHInternational journal of antimicrobial agentsIn vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924.Int J Antimicrob Agents2023-07-09T00:00:002023In vitro model to simulate multiple drugs with distinct elimination half-lives.Authorship 138836true1ChairChairDepartment of Biochemistry and Molecular PharmacologyBiochemistry & Mol PharmacologyAuthorship 1077738737563789Hudson CS, Smith JE, Eales BM, Kajiji S, Liu X, Truong LD, Tam VHThe Journal of antimicrobial chemotherapyZileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.J Antimicrob Chemother2023-10-03T00:00:002023Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model.Authorship 134521Authorship 13971Authorship 152911Authorship 1085136538063509Teran N, Egge SL, Phe K, Baptista RP, Tam VH, Miller WRAntimicrobial agents and chemotherapyThe emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 Jan 10; 68(1):e0100923.Antimicrob Agents Chemother2023-12-08T00:00:002023The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.true1Adjunct ProfessorAdjunct Professortrue1ProfessorProfessorAuthorship 217452Authorship 270572Authorship 229114Authorship 352185Authorship 395324Authorship 278261Authorship 421255Authorship 324431Authorship 1403032Authorship 1412764Authorship 1426686Authorship 143109101494125Wolfaardt JF, Tam V, Faulkner MG, Prasad NThe Journal of prosthetic dentistryMechanical behavior of three maxillofacial prosthetic adhesive systems: a pilot project. J Prosthet Dent. 1992 Dec; 68(6):943-9.J Prosthet Dent1992-12-01T00:00:001992Mechanical behavior of three maxillofacial prosthetic adhesive systems: a pilot project.24359843Ng TM, Lye DC, Chan M, Tam VHInternational journal of antimicrobial agentsPredictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9.Int J Antimicrob Agents2013-11-08T00:00:002013Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion.24566187Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VHAntimicrobial agents and chemotherapyIn vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6.Antimicrob Agents Chemother2014-02-24T00:00:002014In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.24674388Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TMJournal of infection and chemotherapy : official journal of the Japan Society of ChemotherapyAn evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7.J Infect Chemother2013-12-11T00:00:002013An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.Authorship 320861Authorship 32243Authorship 4833Authorship 496612Authorship 375811Authorship 369953Authorship 378731Authorship 575226Authorship 445751Authorship 607996Authorship 624721Authorship 640605Authorship 487412Authorship 149057524733472Abdelraouf K, Chang KT, Yin T, Hu M, Tam VHAntimicrobial agents and chemotherapyUptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2.Antimicrob Agents Chemother2014-04-14T00:00:002014Uptake of polymyxin B into renal cells.Authorship 51576Authorship 728213Authorship 149252824797063Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VHThe Journal of antimicrobial chemotherapyPharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21.J Antimicrob Chemother2014-05-05T00:00:002014Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections.Authorship 733412Authorship 609081Authorship 1506415Authorship 1512382Authorship 151359324957824Tan MW, Lye DC, Ng TM, Nikolaou M, Tam VHAntimicrobial agents and chemotherapyMathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44.Antimicrob Agents Chemother2014-06-23T00:00:002014Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii.25072843Zhang D, Rios DR, Tam VH, Chow DSJournal of pharmaceutical and biomedical analysisDevelopment and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child. J Pharm Biomed Anal. 2014 Oct; 99:67-73.J Pharm Biomed Anal2014-07-10T00:00:002014Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child.25225341Abdelraouf K, Tam VHAntimicrobial agents and chemotherapyReply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339.Antimicrob Agents Chemother2014-10-01T00:00:002014Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?".Authorship 881812Authorship 152858425136012Phe K, Johnson ML, Palmer HR, Tam VHAntimicrobial agents and chemotherapyValidation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.Antimicrob Agents Chemother2014-08-18T00:00:002014Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin.Authorship 662431Authorship 650621Authorship 938696Authorship 955402Authorship 981268Authorship 987276Authorship 705067Authorship 741331Authorship 775776Authorship 777951